SCHEMBL24209703

SCHEMBL24209703

CCc1nnc(NC(=O)CSc2nnnn2-c2ccc(C(=O)O)cc2)s1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.69
▸ HPGD P15428 3/20 0.69
▸ NPSR1 Q6W5P4 3/20 0.63
▸ POLB P06746 2/20 0.58
▸ GAA P10253 1/20 0.55
▸ HTT P42858 1/20 0.55
▸ KMT2A Q03164 4/20 0.55
▸ MEN1 O00255 3/20 0.55
▸ TSHR P16473 4/20 0.54
▸ MAPT P10636 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24209779 0.81 KMT2A (0.76) ALDH1A1HPGDNPSR1GAAKMT2A
SCHEMBL24209702 0.80 MEN1 (0.63) ALDH1A1HPGDNPSR1POLBHTT
SCHEMBL24209903 0.80 NPSR1 (0.68) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL24019617 0.80 NPSR1 (0.71) ALDH1A1HPGDNPSR1POLBKMT2A
SCHEMBL24210088 0.79 KMT2A (0.83) ALDH1A1HPGDNPSR1GAAKMT2A
SCHEMBL24210094 0.78 NPSR1 (1.00) ALDH1A1HPGDNPSR1POLBKMT2A
SCHEMBL25609962 0.77 NPSR1 (0.67) ALDH1A1HPGDNPSR1POLBKMT2A
SCHEMBL24209777 0.77 NPSR1 (0.83) ALDH1A1HPGDNPSR1POLBHTT
SCHEMBL24209749 0.76 KMT2A (0.82) ALDH1A1NPSR1POLBKMT2AMEN1
SCHEMBL24209697 0.76 ALDH1A1 (0.82) ALDH1A1NPSR1POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220016080-A1 COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS FUND PROFESOR NOVOA SANTOS (ES) 2022-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220016080-A1 COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS CHUK, HIPK3, HIPK1 ALDH1A1 967/4885HPGD 1570/4885NPSR1 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback